Search Within

Myeloma

Formats
  1. Meeting Abstract (557)
  2. Journal Article (368)
  3. Review (37)
  4. Research Letter (21)
  5. Book Section (10)
  6. Guidelines (10)
  7. Correspondence (7)
  8. Editorial (5)
  9. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (1016)
  2. Department of Medicine (1016)
  3. Hematologic Malignancies, Division of (1016)
  4. Hematologic Malignancies Research (669)
  5. Survivorship Research (374)
  6. Sloan Kettering Institute Postdocs (306)

More Groups

People
  1. Alexander Lesokhin (381)
  2. Hani Hassoun (339)
  3. Carl Landgren (336)
  4. Sham Mailankody (297)
  5. Malin Hultcrantz (274)
  6. Heather Landau (249)

More People

Years
  1. 2025 (28)
  2. 2024 (82)
  3. 2023 (115)
  4. 2022 (96)
  5. 2021 (76)
  6. 2020 (95)

More Years

Publications
  1. Blood (317)
  2. Clinical Lymphoma, Myeloma and Leukemia (96)
  3. Journal of Clinical Oncology (86)
  4. Haematologica (41)
  5. Biology of Blood and Marrow Transplantation (29)
  6. Blood Cancer Journal (24)

More Publications

Publishers
  1. American Society of Hematology (340)
  2. Elsevier Inc. (160)
  3. American Society of Clinical Oncology (88)
  4. Nature Publishing Group (87)
  5. Ferrata Storti Foundation (41)
  6. American Association for Cancer Research (34)

More Publishers

Results (1016)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • An appraisal of clinically meaningful outcomes guidelines for oncology clinical trials
    Journal Article

    Kumar, H.; Fojo, T.; Mailankody, S.
    JAMA Oncology (2016)

    Fulltext@MSK | Save
  • Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient
    Journal Article

    Landgren, O.; Owen, R. G.
    Cytometry Part B—Clinical Cytometry (2016)

    Fulltext@MSK | Save
  • Controversies in multiple myeloma: Evidence-based update
    Journal Article

    Ahn, I. E.; Mailankody, S.
    Seminars in Oncology (2016)

    Fulltext@MSK | Save
  • A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival
    Journal Article

    Kazandjian, D.; Landgren, O.
    Seminars in Oncology (2016)

    Fulltext@MSK | Save
  • Treatment of high-risk smoldering myeloma
    Journal Article

    Korde, N.
    Seminars in Oncology (2016)

    Fulltext@MSK | Save
  • Combination therapy for fit (younger and older) newly diagnosed multiple myeloma patients: Data support carfilzomib, lenalidomide, and dexamethasone independent of cytogenetic risk status
    Journal Article

    Landgren, O.
    Seminars in Oncology (2016)

    Fulltext@MSK | Save
  • Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: A meta-analysis
    Journal Article

    Landgren, O.; Devlin, S.; Boulad, M.; Mailankody, S.
    Bone Marrow Transplantation (2016)

    Fulltext@MSK | Save
  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
    Journal Article

    Kumar, S.; Paiva, B.; Anderson, K. C.; Durie, B.; Landgren, O.; Moreau, P.; Munshi, N.; Lonial, S.; Bladé, J.; Mateos, M. V.; more...
    Lancet Oncology (2016)

    Fulltext@MSK | Save
  • New developments in diagnosis, prognosis, and assessment of response in multiple myeloma
    Journal Article

    Landgren, O.; Rajkumar, S. V.
    Clinical Cancer Research (2016)

    Fulltext@MSK | Save
  • Increased mortality among men aged 50 years old or above with elevated IgA anti-transglutaminase antibodies: NHANES III
    Journal Article

    Rubio-Tapia, A.; Ludvigsson, J. F.; Choung, R. S.; Brantner, T. L.; Rajkumar, S. V.; Landgren, O.; Murray, J. A.
    BMC Gastroenterology (2016)

    Fulltext@MSK | Save